Minimally Invasive Glaucoma Surgery Devices Market Size, Share and Forecast Trends - Growth Analysis and Outlook Report 2026-2030

MIGS devices include a range of implants, stents, and micro-invasive surgical tools used to improve aqueous humor outflow in glaucoma patients with milder to moderate disease. The market encompasses products such as glaucoma drainage implants, valves, trabecular bypass devices, and suprachoroidal shunts, all designed to reduce intraocular pressure with minimal tissue disruption.

• •Market valued at approximately $1.13 billion in 2025 with projected continued expansion
• •Products include valves, glaucoma drainage implants, and trabecular bypass stents
• •Procedures typically performed in ambulatory surgical centers and hospital outpatient departments

Rising global prevalence of glaucoma, particularly among aging populations, is a primary catalyst for market expansion as earlier intervention becomes more common. The clinical advantages of MIGS over traditional filtering surgery, including reduced complication rates, faster visual recovery, and shorter procedure times, have driven surgeon adoption and patient demand.

• •Growing elderly demographic and increasing glaucoma diagnosis rates worldwide
• •Superior safety profiles and quicker recovery times compared to conventional glaucoma surgeries
• •Favorable reimbursement environments in developed markets supporting procedure volume growth

The market is segmented by product type, including glaucoma drainage devices, suprachoroidal shunts, and subconjunctival implants, each serving different anatomical targets and disease severities. Geographically, North America leads market share due to advanced healthcare infrastructure and high procedure volumes, while Asia-Pacific represents the fastest-growing region driven by rising healthcare access and an expanding elderly population.

• •Product categories span valves, drainage implants, and micro-stents targeting various outflow pathways
• •North America commands the largest regional share, followed by Europe and Asia-Pacific
• •Hospital-based and ambulatory surgery center settings represent primary end-use segments

What are the recent trends and outlook?

The market is moving toward combination procedures performed concurrently with cataract surgery, as this approach maximizes the benefit of both interventions for glaucoma patients. Ongoing device innovation focuses on miniaturization, biocompatible materials, and improved outflow physiology, with new entrants expected to broaden the therapeutic options available.

• •Combined MIGS-plus-cataract procedures becoming standard of care for eligible patients
• •Next-generation devices emphasizing micro-scale designs and sustained pressure control
• •Long-term clinical data accumulation supporting expanded indications and reimbursement coverage